Fig. 1.

Flow chart of the study design. BioMILD screening participants were selected according to the low-dose computed tomography (LDCT) result at the first and subsequent screening rounds (A). At each screening round the selected participants were stratified according to the combined results of LDCT and the microRNA signature classifier (MSC) test (B). LDCT divided patients into CT negative (CT−), CT indeterminate (CTind) and CT positive (CT+), while MSC divided patients into MSC positive (MSC+) and MSC negative (MSC−).